Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial

The multi-center, randomized, open-label, phase III trial discussed in the present study was performed to compare the clinical outcomes of nedaplatin (NDP) plus paclitaxel, and carboplatin (CBP) plus paclitaxel for the treatment of epithelial ovarian cancer (EOC). In the current study, 182 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Zhuang, Qingqing, Cao, Zeyi, Yin, Rutie, Zhu, Yaping, Zhu, Lirong, Xie, Xing, Zhang, Youzhong, Wu, Qiang, Zheng, Jianhua, Zhou, Qi, Li, Xiaoping, Wu, Lingying, Feng, Youji, Wang, Changyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796383/
https://www.ncbi.nlm.nih.gov/pubmed/29467885
http://dx.doi.org/10.3892/ol.2018.7761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796383/
https://www.ncbi.nlm.nih.gov/pubmed/29467885
http://dx.doi.org/10.3892/ol.2018.7761

Ejemplares similares